About Us.
2018
01.
Anti-cancer drug BEY1107: applied for IND for phase I/II clinical trial
Approved as venture company (Venture capital association)
02.
Anti-cancer drug BEY1107: IND approved for phase I/II clinical trial
04.
Granted from Ministry of Health and Welfare (MOHW) (2 year)
Series C investment raised (allotment to third party)
05.
Anti-cancer drug BEY1107: begins phase I/II clinical trial
2017
01.
Anti-Alzheimer drug BEY2153: entered into non-clinical study (GLP)
BEY4101: entered into non-clinical study (GLP)
04.
Granted from Ministry of Science and ICT (MSIT) (5 year)
08.
Applied for patent in major foreign countries
09.
Domestic product patent registered
12.
Industrial land allotted at International Science Business Belt (Dungok district)
2016
06.
Anti-cancer drug BEY1107: completed non-clinical study (GLP)
Series B investment raised (allotment to third party)
2015
01.
Anti-cancer drug BEY1107: entered into non-clinical study (GLP)
06.
Granted from Ministry of Science and ICT (MSIT) (5 year)
12.
Approved as venture company (Venture capital association)
2014
03.
Approved as company-affiliated R&D center
05.
Granted from Small Medium Business Administration (SMBA)
06.
Series A investment raised (allotment to third party)
08.
Granted from Daejeon Technopark
11.
Granted from Small Medium Business Administration (SMBA)
12.
Granted from Ministry of Science and ICT (MSIT) (2 year)
2013
06.
Founded BeyondBio Inc.
11.
Approved as Research & Development Dedicated Department
12.
Approved as venture company (Korea Technology Finance Corporation)
42, Gukjegwahak 13-ro, Yuseong-gu, Daejeon, 34002, Rep of Korea
Copyright (c) 2010 BEYONDBIO Inc. All rights reserved.
